Dietary Exposure
Conditions
Keywords
Dietary antiplatelet, Lipid profile, Endothelial activation, Cardiovascular disease
Brief summary
The study is a prospective, controlled, randomized two-arm longitudinal crossover trial, performed in a single-centre. Hence, the investigators designed a clinical study aimed to investigate the effects of a daily intake of soffritto in overweight or obese class-1 individuals without other cardiovascular risk. After a run-in period of two-week, participants were randomly separated in two different intervention sequences (two-arms) of six-weeks in which volunteers were administered with a soffritto (100 g/day) or a control group (without soffritto). After the first six-week period, participants had a wash-out phase of two-week followed by a second six-week period in which groups exchanged their interventions. During the duration of the study, the volunteers were asked to maintain their usual diet, excluding raw or cooked tomatoes, as well as tomato-based products (sauces, ketchup, juices, etc.) other than those administered during the study in the corresponding periods.
Detailed description
Sample size (N= 40) was calculated according results of previous studies on pigs (http://dx.doi.org/10.1016/j.trsl.2014.11.004). The study refers to healthy adult men (n=27) and women (n=13) with ages ranging from 25 to 60 years, non-smokers and with overweight (BMI: 25.0-29.9 kg/m2) or obesity class 1 (BMI: 30-34.9 kg/m2). This study received approval from the Human Ethical Review Committee of Hospital Santa Creu I Sant Pau (Barcelona), with the reference number 12/181 and the date of approval being January 11, 2013. To confirm health status, all subjects underwent a complete physical examination conducted by the study physician. The study lasted 16 weeks that were structured in: * 2 weeks of run-in. * 6 weeks of intervention period. During the intervention period, volunteers were administered with soffritto (100 g/day) or a control group (without soffritto). * 2 weeks of wash-out. * 6 weeks of intervention period. During the intervention period, volunteers exchanged their interventions The volunteers visited the center at days 0, 14, 56, 70 and at the end of the intervention period (day 112). Dietary habits were collected. Compliance was monitored by weekly telephone contact with participants and interviewing them at the end of each intervention period. Blood samples were collected early at the morning after twelve-hour fasting at baseline and at the end of each intervention phase. Blood samples were used for determining all variables of the study. Stool samples were obtained at baseline and after 42 days intervention for the study of platelet aggregation, lipid profile, biochemical measurements, vascular endothelial function and hemogram profile.
Interventions
OTHERSoffritto
The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks. This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).
Sponsors
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
The intervention trial consisted of a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial with a total duration of 16 weeks, which includes 2-weeks run-in period, 6 week intervention period (soffito or control group), 2-weeks wash-out period and 6 week intervention period (soffito or control group).
Eligibility
Sex/Gender
ALL
Age
25 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Men and Women 25-60 years of age * BMI: \>28 Kg/m2
Exclusion criteria
* Ischemic heart disease (and/or previous angina or AMI) * Less than 25 years old and more than 60 years old * Current/previous history of arrhythmia * Cardiovascular co-morbidity (previous cardiovascular accidents and/or peripheral vascular disease) * On current treatment with vasoactive drugs, fibrates or statins (see exception) * Alcohol consumption of more than 60 gr/day * Renal insufficiency (creatinine \> 2 mg/dl) * Presence of neoplasia * Presence of systemic disease * Psychiatric disease in treatment with psychotropic drugs * Secondary dyslipidemia (nephrotic syndrome, hypothyroidism, others...) * Being in a weight loss phase or expressing a desire for weight loss during the 3 months of the study duration. * Having taken aspirin in the 10-day period prior to blood sampling.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline of platelet aggregation (induced by different agonists: arachidonic acid [1 mM], collagen [2 and 5 µM] and ADP [5 and 20 µM] at day 42 | At days 0 and 42 | By the light transmission technique LTA. For all agonist results were expressed as the percentage of variation respect to the baseline value (100%). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline of standard serum lipid profile (total cholesterol, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol and triacylglycerols expressed as mg/dL) at day 42 | At days 0 and 42 | Routine commercially available assays were used for triglycerides, total cholesterol and high density lipoprotein cholesterol. Low density lipoprotein cholesterol was calculated using the Friedewald equation |
| Changes from baseline of vascular endothelial function (RHI, lnRHI, FRHI and AI@75) at day 42 | At days 0 and 42 | Digital plethysmography using the EndoPAT2000-device. Endothelial function was given as the reactive hyperaemia index (RHI) and the arterial stiffness as the augmentation index (AI) and AI standardized to a pulse of 75/min (AI@75). The natural logarithmically transformed RHI (lnRHI) values was also calculated. The Framingham RHI (FRHI) was calculated as the natural log-transformation of the RHI |
| Changes from baseline of hemogram profile at day 42 | At days 0 and 42 | Digital plethysmography using the EndoPAT2000-device |
| Changes from baseline of glucose levels at day 42 | At days 0 and 42 | Using routine commercially available assays |
| Changes from baseline of hepatic enzymes (ALT, AST and GGT) at day 42 | At days 0 and 42 | Using routine commercially available assays |
| Changes from baseline of renal markers (creatinine, urea and uric acid) at day 42 | At days 0 and 42 | Using routine commercially available assays |
| Changes from baseline of BMI at day 42 | At days 0 and 42 | Dividing the body weight in kilograms by the square of height in meters (kg/m2) |
| Changes from baseline of hemodynamic profile at day 42 | At days 0 and 42 | Blood pressure monitor (Sphygmomanometer) |
Countries
Spain
Outcome results
None listed